Atenolol-associated cholestasis.
Atenolol, a beta 1-selective beta-adrenergic receptor-blocking agent, is frequently used for the treatment of hypertension and angina pectoris. We report our experience with a patient who developed cholestatic hepatitis related to the initiation of therapy with atenolol with prompt resolution of symptoms and biochemical abnormalities upon discontinuation of this medication. A review of the literature failed to demonstrate any prior report of atenolol-associated hepatic injury. Although rare, because of the common use of atenolol, clinicians should be aware of this potential adverse effect.
Schwartz
M S
MS
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Frank
M S
MS
Yanoff
A
A
Morecki
R
R
D000368:Aged; D001262:Atenolol / Q000009:adverse effects*; D002779:Cholestasis / Q000139:chemically induced*; D006801:Humans; D008297:Male
D001262:Atenolol